Breaking News Instant updates and real-time market news.

CELG

Celgene

$93.80

-0.76 (-0.80%)

09:05
06/03/19
06/03
09:05
06/03/19
09:05

Celgene announces updated analysis of data from Phase 2 JAKARTA2 clinical study

Celgene announced an updated analysis of data from the Phase 2 JAKARTA2 clinical study demonstrating clinically meaningful response rates with investigational fedratinib in patients with myelofibrosis previously treated with ruxolitinib. "This updated analysis of fedratinib employed intent-to-treat, or ITT, principles and utilized a narrower definition of ruxolitinib relapsed, refractory, or intolerant patients. Results were shared in a poster presentation today at the 2019 American Society of Clinical Oncology, or ASCO, Annual Meeting in Chicago. In the ITT population, the proportion of patients who exhibited a 35% or greater reduction in spleen volume at end of cycle 6 was 31%. Of these 97 patients, 79 met the narrower criteria for ruxolitinib resistance or intolerance. In this cohort, the proportion of patients who exhibited a 35% or greater reduction in spleen volume at end of cycle 6 was 30%, consistent with the response rate observed in the ITT population. In addition, the proportion of patients who exhibited a 50% or greater symptom response rate was 27% in both the ITT population and the patients in the analysis of the narrower criteria. The most common grade 3-4 hematologic abnormalities were anemia and thrombocytopenia. Most common non-hematologic treatment-emergent adverse events in all treated patients were diarrhea, nausea, vomiting, and constipation."

  • 27

    Jun

  • 03

    Sep

CELG Celgene
$93.80

-0.76 (-0.80%)

05/03/19
JPMS
05/03/19
INITIATION
Target $62
JPMS
Overweight
Bristol-Myers reinstated with an Overweight at JPMorgan
Following a period of restriction, JPMorgan analyst Chris Schott reinstated coverage of Bristol-Myers Squibb (BMY) with an Overweight rating and $62 price target. The analyst had an Overweight rating on the shares and price target of $70 prior to restriction. While the company's proposed acquisition of Celgene (CELG) has been controversial, the shares are "too inexpensive to ignore," Schott tells investors in a research note. He sees the combined company generating 2020 earnings of $6.50 per share and 3% sales/6% earnings growth off of this base through 2025.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $23
PIPR
Overweight
Sutro regaining U.S. rights from Celgene a 'clear positive,' says Piper Jaffray
The FDA has cleared the investigational new drug application for Sutro Biopharma's Celgene-partnered BCMA ADC, which is on track to enter the clinic in 2019, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. In addition, Celgene not exercise an option on a second program, meaning Sutro has regained U.S. rights, adds the analyst. He views this as a "clear positive" for Sutro, saying the company has regained the U.S. rights to "another exciting preclinical program." Importantly, there is no impact on Sutro's wholly-owned clinical programs, Tenthoff adds. He reiterates an Overweight rating on Sutro Biopharma with a $23 price target.
05/20/19
05/20/19
DOWNGRADE

Hold
Bristol-Myers downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded Bristol-Myers (BMY) to Hold from Buy, saying he has "serious concerns" about the company's growth prospects after its announced acquisition of Celgene (CELG). The analyst contends that Celgene's pipeline is not sufficient to offset the expected decline in revenues from its Revlimid, which will lose exclusivity in 2026. Toung adds that Bristol-Myers' "patent cliff" is also notable with loss of exclusivity expected for Opdivo in 2028, Eliquis in 2026, and Orencia in 2021. While the stock trades at 10.5-times forward earnings multiple - a discount to the 12-times peer group average - the analyst believes the valuation is appropriate.
05/28/19
GSCO
05/28/19
INITIATION
Target $54
GSCO
Buy
Bristol-Myers initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Bristol-Myers Squibb with a Buy rating and $54 price target. Bristol-Myers is trading at a "significant discount to the group," Flynn tells investors in a research note. The analyst says his call is based on valuation, and he sees potential for multiple expansion whether or not the Celgene (CELG) acquisition closes.

TODAY'S FREE FLY STORIES

03:05
10/14/19
10/14
03:05
10/14/19
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
10/14/19
10/14
03:05
10/14/19
03:05
General news
FX Update: Currencies have opened the week in undramatic fashion »

FX Update: Currencies…

XLNX

Xilinx

$96.18

3.4 (3.66%)

, INTC

Intel

$52.06

0.95 (1.86%)

20:45
10/13/19
10/13
20:45
10/13/19
20:45
Upgrade
Xilinx, Intel rating change at Nomura Instinet »

Xilinx upgraded to Buy…

XLNX

Xilinx

$96.18

3.4 (3.66%)

INTC

Intel

$52.06

0.95 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 20

    Nov

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:49
10/13/19
10/13
19:49
10/13/19
19:49
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

FB

Facebook

$184.20

4.02 (2.23%)

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

TGT

Target

$111.86

1.29 (1.17%)

T

AT&T

$37.58

0.17 (0.45%)

ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

NUE

Nucor

$52.69

2.48 (4.94%)

PNR

Pentair

$37.33

1.215 (3.36%)

GWW

Grainger

$305.24

16.49 (5.71%)

K

Kellogg

$62.14

-0.27 (-0.43%)

ATVI

Activision Blizzard

$54.80

1.1 (2.05%)

TTWO

Take-Two

$122.42

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 18

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

IGMS

IGM Biosciences

$17.53

-0.125 (-0.71%)

19:42
10/13/19
10/13
19:42
10/13/19
19:42
Initiation
IGM Biosciences initiated at Piper Jaffray »

IGM Biosciences initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

19:37
10/13/19
10/13
19:37
10/13/19
19:37
Hot Stocks
LeMaitre acquires biologic patch business from Admedus »

LeMaitre Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

18:37
10/13/19
10/13
18:37
10/13/19
18:37
Periodicals
SoftBank seeking control of WeWork through financing package, WSJ says »

SoftBank (SFTBY) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KOD

Kodiak Sciences

$18.24

1.34 (7.93%)

18:34
10/13/19
10/13
18:34
10/13/19
18:34
Hot Stocks
Kodiak Sciences announces safety, efficacy from Phase 1b study of KSI-301 »

Kodiak Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:29
10/13/19
10/13
18:29
10/13/19
18:29
Recommendations
Adverum Biotechnologies analyst commentary at Piper Jaffray »

Adverum '022 looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:23
10/13/19
10/13
18:23
10/13/19
18:23
Hot Stocks
Adverum Biotechnologies reports additional data from Phase 1 trial of ADVM-022 »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$56.41

0.55 (0.98%)

18:03
10/13/19
10/13
18:03
10/13/19
18:03
Hot Stocks
ConocoPhillips announces $1.39B agreement to sell interests in Australia-West »

ConocoPhillips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.58

0.17 (0.45%)

, CMCSA

Comcast

$45.53

1.02 (2.29%)

17:18
10/13/19
10/13
17:18
10/13/19
17:18
On The Fly
Box Office Battle: 'Joker' stays at number 1 with another $55M »

"Box Office Battle" is…

T

AT&T

$37.58

0.17 (0.45%)

CMCSA

Comcast

$45.53

1.02 (2.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$58.16

0.83 (1.45%)

LGF.A

Lionsgate

$9.52

0.22 (2.37%)

LGF.B

Lionsgate

$8.97

0.19 (2.16%)

DIS

Disney

$130.08

0.73 (0.56%)

VIAB

Viacom

$23.02

0.505 (2.24%)

VIA

Viacom

$25.45

0.65 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

PCG

PG&E

$8.08

0.3 (3.86%)

16:48
10/13/19
10/13
16:48
10/13/19
16:48
Periodicals
PG&E turns down San Francisco's $2.5B offer to acquire assets, Reuters says »

PG&E rejected a $2.5B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

TTGT

TechTarget

$22.64

0.14 (0.62%)

, SKHCY

Sonic Healthcare

$0.00

(0.00%)

16:44
10/13/19
10/13
16:44
10/13/19
16:44
Conference/Events
Commvault to hold a conference »

Commvault GO 2019 will be…

TTGT

TechTarget

$22.64

0.14 (0.62%)

SKHCY

Sonic Healthcare

$0.00

(0.00%)

NTAP

NetApp

$51.50

1.74 (3.50%)

HPE

HP Enterprise

$14.35

0.24 (1.70%)

HLF

Herbalife Nutrition

$39.07

0.51 (1.32%)

FORR

Forrester

$32.43

0.61 (1.92%)

CSCO

Cisco

$46.52

0.38 (0.82%)

CVLT

Commvault

$45.51

0.695 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 29

    Oct

  • 29

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 12

    Dec

FB

Facebook

$184.20

4.02 (2.23%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Periodicals
Warren buying Facebook ads claiming Zuckerberg backs Trump, Bloomberg says »

Elizabeth Warren is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

KBH

KB Home

$33.92

-0.15 (-0.44%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Conference/Events
SunTrust to hold a field trip »

Field Trip with KB Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

BX

Blackstone

$47.10

0.62 (1.33%)

16:34
10/13/19
10/13
16:34
10/13/19
16:34
Periodicals
Blackstone discussed with Citadel about buying stake, WSJ reports »

Blackstone has held talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

16:29
10/13/19
10/13
16:29
10/13/19
16:29
Periodicals
Google bars high-interest consumer loan services from app store, WSJ reports »

Google has barred…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

16:28
10/13/19
10/13
16:28
10/13/19
16:28
General news
Trump working with Congress on 'powerful' Turkey sanctions »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23
Hot Stocks
Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies »

Allergan and Molecular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$39.49

1.8 (4.78%)

, UBER

Uber

$30.09

1.19 (4.12%)

16:04
10/13/19
10/13
16:04
10/13/19
16:04
Periodicals
Lyft sues NYC over cruising time caps, Reuters reports »

Following its rival…

LYFT

Lyft

$39.49

1.8 (4.78%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

GM

General Motors

$35.57

0.9 (2.60%)

15:59
10/13/19
10/13
15:59
10/13/19
15:59
Periodicals
UAW boosting strike pay as General Motor walkout continues, Reuters says »

The United Auto Workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49
Periodicals
Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says »

Health authorities in…

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

HMTV

Hemisphere Media

$11.70

0.05 (0.43%)

15:48
10/13/19
10/13
15:48
10/13/19
15:48
Initiation
Hemisphere Media initiated at Wells Fargo »

Hemisphere Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37
Hot Stocks
Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD »

Pfizer announced complete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.